[
    [
        {
            "time": "",
            "orginal_text": "药品审评审批工作程序获优化，老百姓、药企都将受益！",
            "features": {
                "keywords": [
                    "药品审评",
                    "审批程序",
                    "优化",
                    "老百姓",
                    "药企"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药品审评审批工作程序获优化，老百姓、药企都将受益！",
            "scores": {
                "News_content": "药品审评审批工作程序获优化，老百姓、药企都将受益！",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "辉瑞新药多韦替利获批，PARP抑制剂全球市场四分天下",
            "features": {
                "keywords": [
                    "辉瑞",
                    "新药",
                    "多韦替利",
                    "PARP抑制剂",
                    "全球市场"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "辉瑞新药多韦替利获批，PARP抑制剂全球市场四分天下",
            "scores": {
                "News_content": "辉瑞新药多韦替利获批，PARP抑制剂全球市场四分天下",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "江苏上市公司创新百强榜出炉 珠港澳大桥见证了这家公司实力",
            "features": {
                "keywords": [
                    "江苏",
                    "上市公司",
                    "创新百强榜",
                    "珠港澳大桥"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "江苏上市公司创新百强榜出炉 珠港澳大桥见证了这家公司实力",
            "scores": {
                "News_content": "江苏上市公司创新百强榜出炉 珠港澳大桥见证了这家公司实力",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业研究简报:境外新药上市加快,深圳gpo细则公布",
            "features": {
                "keywords": [
                    "医药生物",
                    "境外新药",
                    "上市加快",
                    "深圳gpo",
                    "细则公布"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业研究简报:境外新药上市加快,深圳gpo细则公布",
            "scores": {
                "News_content": "医药生物行业研究简报:境外新药上市加快,深圳gpo细则公布",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业周报:药品信息化追溯体系建设加快推进",
            "features": {
                "keywords": [
                    "医药行业",
                    "药品信息化",
                    "追溯体系",
                    "建设推进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药行业周报:药品信息化追溯体系建设加快推进",
            "scores": {
                "News_content": "医药行业周报:药品信息化追溯体系建设加快推进",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]